Thursday, November 06, 2025
Early-Stage Clinical Trial Demonstrates Promise of Intranasal Influenza Vaccine in Generating Broad Immunity
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 “bird flu”. The study, published today in the journal Nature Communications, highlights the potential of mucosal immunization strategies--where vaccines are sprayed into the nostrils--to prime immune defenses against diverse influenza strains.
Friday, October 17, 2025
New Monoclonal Antibody Shows Promise for Preventing Malaria Infections
Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives each year worldwide with limited efficacy in currently available treatments and vaccines. Now a new early-stage clinical trial found that a novel monoclonal antibody provided dose-dependent full protection against the malaria parasite with minimal side effects.
Wednesday, October 08, 2025
New Vaccine Shows Promise Against Typhoid and Invasive Salmonella in First Human Trial
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) have completed a successful Phase 1 clinical trial of a novel vaccine designed to protect against both typhoid fever and invasive non-typhoidal Salmonella--two major causes of illness and death among children in sub-Saharan Africa.
Monday, September 08, 2025
Internationally Recognized Malaria Researcher Stefan Kappe, PhD, Appointed New Director of the UM School of Medicine's Center for Vaccine Development and Global Health
University of Maryland School of Medicine Dean, Mark T. Gladwin, MD, announced today the appointment of distinguished parasitologist and immunologist Stefan Kappe, PhD, to be the new Director of the school’s Center for Vaccine Development and Global Health (CVD). Known for his landmark research on the early phases of malaria parasite infection in the liver, Dr. Kappe is a Professor and the Associate Vice Chair of Basic Science Research in the Department of Pediatrics at the University of Washington in Seattle. He is also a senior principal investigator at the Center for Global Infectious Disease Research at Seattle Children’s Research Institute where he until recently also served as an Associate Director.
Thursday, April 17, 2025
Faculty Address Future of Federal Research Funding in National Media Panel
Researchers at the University of Maryland, Baltimore addressed members of the media on Thursday, April 3 to discuss ongoing impacts of cuts to federally funded medical research and the future of academic medicine. From the potential of GLP-1 antagonists, like Ozempic, in addiction medicine to blood tests for early cancer diagnosis, researchers provided reporters an inside look at how lifesaving interventions could be hampered by the loss of federal funding.
Wednesday, March 12, 2025
Meningococcal Vaccine Found to be Safe and Effective for Infants in Sub-Saharan Africa
University of Maryland School of Medicine (UMSOM) researchers helped conduct an important new global health study that found a vaccine that protects against five strains of meningitis prevalent in sub-Saharan Africa is safe and effective for use in young children beginning at 9 months of age. This study provided evidence that formed the basis for the World Health Organization’s (WHO) decision last year to recommend the pentavalent Men5CV meningitis vaccine for infants ages 9 months and older.